STOCK TITAN

Exelixis (EXEL) insider Patrick Haley files to sell 67,814 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Exelixis insider Patrick Joseph Haley has filed a notice to sell up to 67,814 shares of the company’s common stock under Rule 144. The planned sale, through Morgan Stanley Smith Barney, has an indicated aggregate market value of $2,951,082.94 based on the figures in the notice.

The shares to be sold were acquired as performance shares from the issuer on January 15, 2026 (37,421 shares) and February 15, 2026 (30,393 shares), with payment listed as not applicable. The notice also shows that Haley previously sold common shares during November 2025 in three transactions totaling tens of thousands of shares, with individual gross proceeds of $1,194,070.94, $421,052.00, and $1,431,757.23.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does Patrick Joseph Haley’s Form 144 filing for EXEL indicate?

The Form 144 shows Patrick Joseph Haley intends to sell up to 67,814 EXEL common shares under Rule 144. The filing lists an aggregate market value of $2,951,082.94 and identifies Morgan Stanley Smith Barney as the broker handling the planned sale.

How many EXEL shares is Patrick Joseph Haley planning to sell under Rule 144?

The notice states that 67,814 shares of Exelixis common stock are proposed to be sold. These shares are to be sold through Morgan Stanley Smith Barney and are tied to performance share awards acquired in January 2026 and February 2026.

What is the indicated market value of the EXEL shares in this Form 144?

The Form 144 lists an aggregate market value of $2,951,082.94 for the 67,814 Exelixis common shares proposed for sale. This figure reflects the valuation used in the notice for Rule 144 compliance and disclosure purposes.

How were the EXEL shares in Patrick Joseph Haley’s Form 144 acquired?

The shares were acquired as performance shares directly from the issuer. The filing shows 37,421 shares acquired on January 15, 2026 and 30,393 shares on February 15, 2026, with the nature of payment described as not applicable.

What prior EXEL stock sales by Patrick Joseph Haley are disclosed?

The notice lists three prior common stock sales in November 2025: 28,043 shares for $1,194,070.94, 10,000 shares for $421,052.00, and 34,187 shares for $1,431,757.23. These transactions occurred within three months preceding the new planned sale.

On which exchange are the EXEL shares in the Form 144 listed?

The Form 144 specifies that the Exelixis common shares are listed on the NASDAQ. The broker named for the planned Rule 144 sale is Morgan Stanley Smith Barney, operating out of its New York Plaza address, according to the filing details.

Who is the broker for Patrick Joseph Haley’s planned EXEL share sale?

The broker listed is Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004. This firm is designated to handle the sale of 67,814 Exelixis common shares under Rule 144.
Exelixis Inc

NASDAQ:EXEL

EXEL Rankings

EXEL Latest News

EXEL Latest SEC Filings

EXEL Stock Data

11.41B
261.54M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
ALAMEDA